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on HA epitopes that were present in viral strains that they encountered in childhood. 48
Importance 50
Influenza vaccine strains must be updated frequently since circulating viral strains 51 continuously change in antigenically important epitopes. Our previous studies have 52 demonstrated that some individuals possess antibody responses that are narrowly 53 focused on epitopes that were present in viral strains that they encountered during 54 childhood. Here, we show that influenza viruses rapidly escape this type of polyclonal 55 antibody response when grown in ovo by acquiring single mutations that directly prevent 56 antibody binding. These studies improve our understanding of how influenza viruses 57 evolve when confronted with narrowly focused polyclonal human antibodies. 58 59
Introduction 60
Influenza viruses continuously acquire mutations in antigenically important 61 regions of the hemagglutinin (HA) and neuraminidase (NA) proteins through a process 62 termed 'antigenic drift' (1). Most humans are infected with influenza viruses in 63 childhood (2) and then continuously re-infected with antigenically distinct strains later in 64 life (3). Early childhood influenza infections can leave lifelong immunological 'imprints' 65 that can influence how an individual subsequently responds to antigenically distinct 66 influenza strains (4, 5) . Antibody responses in some individuals can become heavily 67 focused on HA epitopes that are conserved between contemporary viral strains and 68 strains that they encountered in childhood (4). It is thought that memory B cells 69 established from childhood infections are continuously recalled later in life upon 70 infection with new influenza virus strains that possess some shared epitopes (4). 71
Seasonal influenza vaccines need to be continually updated because of antigenic 72 drift (6). Understanding the specificity of common human anti-influenza virus antibodies 73 is important to guide the selection of appropriate seasonal vaccine strains. Selection of 74 appropriate vaccine strains also requires a deep mechanistic understanding of how 75 influenza viruses escape human antibodies. Multiple studies suggest that influenza 76 viruses utilize distinct escape mechanisms depending on the complexity of the antibody 77 response they encounter (as reviewed in (1)). For example, influenza viruses grown in 78 vitro or in ovo in the presence of a single HA monoclonal antibody rapidly acquire single 79 HA mutations that prevent the binding of the selecting monoclonal antibody (7) . In 80 contrast, viruses grown in vitro in the presence of multiple HA monoclonal antibodies 81 targeting distinct epitopes (8) or in the presence of polyclonal sera in vivo in mice (9) 82 5 acquire single HA 'adsorptive' mutations that increase viral attachment to host 83 receptors. Adsorptive mutations do not always directly prevent antibody binding-84 instead, viruses with stronger binding avidity can circumvent antibodies of various 85 specificities by simply binding to cells more efficiently (8, 9) . 86
It is unknown if some humans possess polyclonal antibodies that are so biased 87 towards a single HA epitope that they select for single antigenic escape variants similar 88 to what has been previously reported for single monoclonal antibodies. Here, we used 89 hemagglutination-inhibition (HAI) assays and enzyme-linked immunosorbent assays 90 (ELISAs) to identify three human serum samples that possessed anti-H1N1 HA 91
antibodies that were narrowly focused on an epitope that was conserved in an H1N1 92 strain that circulated during their childhood. We sequentially passaged the 93 A/California/07/2009 H1N1 strain in the presence of these serum samples in ovo and 94 characterized the passaged viruses. 95 96
Materials and methods 97
Human Samples. Serum samples were previously collected from human participants in 98 7 presence of 1:40 dilution of serum (i.e. the highest amount of serum without complete 129 neutralization). Similar to the first passage, we incubated different dilutions of each 130 human serum sample (1:10, 1:40, 1:160) with 4x10 5 TCID50 of virus isolated from 131 passage 1 in a total volume of 50ul for 30 minutes at 23 o C. These serum/virus mixtures 132 were injected into embryonated chicken eggs (1 egg per serum/virus mixture) and 133 allantoic fluid was collected three days later. Viral titers in allantoic fluid for the second 134 passage were determined by TCID50 using MDCK cells. We carried out the third 135 passage in the same manner as the second passage. 136 137 Sequencing. Bulk RNA was extracted from allantoic fluid samples using the QIAamp 138 Viral RNA Mini Kit (QIAGEN) according to manufacturer's instructions. Previously 139 described primers were used for full-length amplification of the influenza A genome. 140
Reverse transcription was performed using Superscript III First-Strand Reaction Mix 141 (Thermo Fisher) and an equimolar mix of the 5'-Hoffmann-U12-A4 and 5'-Hoffmann-142 U12-G4 primers, which bind to the conserved U12 region present on each influenza 143 gene segment (12). 1uL annealing buffer and 1uL of 2 uM primer mix were added to 144 6uL RNA eluent, then incubated at 65 o C for 5 min. 10 uL 2X First-Strand Reaction Mix 145 and 2uL Superscript III/RNaseOUT Enzyme Mix were added on ice for a 20uL total 146 reaction volume, then incubated at 25 o C for 10 min, 50 o C for 50 min, and 85 o C for 5 147 min. The entire 20uL volume of the reverse-transcription reaction was used as template 148 in a 100uL PCR reaction using KOD HotStart Reaction Mix (EMP Millipore) and a 24-149 primer cocktail at a total concentration of 600 nM as previously described (13 Processing of Sequence Data. We removed from downstream analysis samples that 161 did not have at least 10,000 raw sequencing reads. Raw sequencing reads were 162 mapped to the flu genome with bwa, using default parameters. The samtools package 163 was used to sort and index alignment files (.bam) and then to convert them to .pileup 164 format which were used as input for varscan mpileup2cns (--min-coverage 30, --min-165 var-freq 0.01) to call mutations. A custom R script calculated each mutation's amino 166 acid position based on its nucleotide position within each segment. 167 168 Quality Filtering. Because sequencing errors are more common towards the end of 169 each viral gene segment, we manually inspected mutations within control samples and 170 determined positional cutoffs for each segment. For the HA segment, we removed 171 mutations outside of nucleotides 1-1,667; for M, 5-1,011; for NP, 5-1,548; for NS1, 5-172 874; for PA, 5-2,217; for PB1, 14-2,326; for PB2, 5-2,325. We did not filter mutations on 173 NA based on position. We then removed mutations that did not appear in at least 2 9 technical replicates within each sample. Finally, we removed mutations with an average 175 allele frequency less than 2.5%, which was the highest average frequency seen in any 176 of the CV (amplicon) samples. with and without amino acid substitutions were produced. We used HAs that possess a 190 Y98F substitution which prevents HA binding to sialic acid (14). It has previously been 191
shown that Y98F has minimal effects on antigenic structure (15). VLPs with HA that 192 has the Y98F substitution can be produced in the absence of NA, which is 193 advantageous for studying anti-HA antibodies in polyclonal sera. For VLP production, 194
we transfected 293T cells (90% confluent in T175 flask) with plasmids expressing HIV 195 gag (36ug), HAT (human airway trypsin-like protease) (0.54ug), and each HA (3.6ug) 196 using polyethylenimine transfection reagent. We isolated culture supernatants and 10 concentrated VLPs using a 20% sucrose cushion. HA amounts in each VLP 198 preparation were determined via ELISAs using the 146-B09 or 065-C05 monoclonal 199 antibodies which bind to conserved regions of the H1 head and stalk, respectively (16). 200 201 ELISAs. ELISA plates were coated overnight at 4 o C with VLPs. ELISA plates were 202 blocked with a 3% (wt/vol) BSA solution in PBS for 2 hours. Plates were washed three 203 times with ddH2O, and serial dilutions of each serum sample were added to plates in 204 1% BSA in PBS. After 2 hours of incubation, plates were washed again and a 205 peroxidase-conjugated anti-human secondary antibody (product number 109-036-098; 206 Jackson ImmunoResearch) or a peroxidase-conjugated anti-mouse secondary antibody 207 (MP Biomedicals) diluted in 1% (wt/vol) BSA solution was added. After a one hour 208 incubation, plates were washed, and a 3,3′,5,5′-tetramethylbenzidine (TMB) substrate 209 (product number 50-00-03; Seracare) was added. HCl was added to stop TMB 210 reactions, and absorbances were measured using a plate reader. One-site specific 211 binding curves were fitted in Prism software. After background subtraction (from ELISA 212 plates that did not have VLPs), serum binding to each VLP relative to the vaccine strain 213 was determined using area under the curve. Equivalent coating of each plate was 214 verified using the 065-C05 or 146-B09 monoclonal antibodies (16). 215
216
Results 217
Identification of individuals who possess narrowly focused anti-H1N1 antibodies. 218
We have previously shown that some individuals born before 1985 possess anti-H1N1 219 antibodies that target an HA epitope that is conserved between the A/California/07/2009 220 pandemic H1N1 strain and seasonal H1N1 strains that circulated prior to 1985 (11, 17) . 221
This particular antibody specificity appears to be important, since contemporary H1N1 222 strains (which are descendants of the 2009 pandemic strain) have acquired several 223 substitutions in the HA epitope targeted by these antibodies over the past 5 years ( Fig.  224 1A-B). For example, H1N1 viruses acquired a K166Q substitution in this epitope during 225 the 2013-2014 season, a S165N substitution in this epitope during the 2015-2016 226 season, and a S167T substitution in this epitope during the 2016-2017 season ( Fig. 1A-227 B) (H3 numbering used throughout this manuscript). While it is clear that antibodies 228 targeting H1N1 HA epitopes involving residues 165-167 are unable to recognize H1N1 229 viruses that are currently circulating among humans, it is unknown whether these 230 antibodies are present in sufficient quantities within single individuals to actually select 231 for HA antigenic escape variants with substitutions at residues 165, 166, and 167. 232
We examined serum samples collected from human donors prior to the 2013-233 2014 influenza season (10, 17). We identified three donors that were born prior to 1985 234 who possessed serum antibodies that had >4 fold reduction in hemagglutination-235 inhibition (HAI) titers using an A/California/07/2009 strain engineered to possess a 236 K166Q HA mutation (herein referred to as H1N1-K166Q) compared to the original 'wild 237 type' A/California/07/2009 strain (H1N1-WT) (Fig. 1C ). We also identified three donors 238 that possessed serum antibodies that had similar HAI titers using the H1N1-K166Q and 239 H1N1-WT strains (Fig. 1C ). HAI assays only detect antibodies that target epitopes near 240 the receptor binding domain in the HA globular head. For that reason, we further 241 characterized each serum sample via ELISAs designed to detect antibodies that bind to 242 both the HA globular head and stalk domains. For ELISA experiments, we engineered 243 a panel of virus-like particles (VLPs) that possess A/California/07/2009 HA with different 244 single point mutations in the HA head and stalk domain (Fig. 2) . As expected, serum 245 antibodies from the three donors that reacted poorly with H1N1-K166Q in HAI assays 246 also bound poorly to VLPs possessing HA with the K166Q substitution ( Fig. 3A-C) . 247
Serum antibodies from donor #1 also had slightly reduced binding to VLPs possessing 248 HA with the N129Y substitution ( Fig. 3A) and antibodies from donor #3 had slightly 249 reduced binding to VLPs possessing HA with the K163E mutation ( Fig. 3C) , both of 250 which are adjacent to HA residue 166 (Fig. 2) . Serum antibodies from donors with 251 narrowly focused HAI responses did not have reduced binding to VLPs possessing 252 substitutions in the lower globular HA head and stalk domains ( Fig. 3D-F) . Serum 253 antibodies from the three donors that had similar HAI titers using the H1N1-K166Q and 254 H1N1-WT viruses did not have reduced binding to any mutant VLPs in our panel, 255
including VLPs possessing HA with the K166Q substitution ( Fig. 4A-F) . None of the HA 256 substitutions in our VLP panel significantly affected binding of serum antibodies from 257 these three individuals. This could be because these donors possess antibodies that 258 target HA epitopes that are not mutated in our VLP panel. Alternatively, it is possible 259 that these donors have more balanced antibody responses and that our assays are not 260 sensitive enough to detect small reductions in polyclonal antibody binding to each VLP. 261 262 Sequential passaging of H1N1 in ovo in the presence of human serum samples. 263
To determine how H1N1 viruses evolve when confronted with narrowly focused serum 264 polyclonal antibody responses, we passaged A/California/07/2009 virus in embryonated 265 chicken eggs in the presence of each serum sample. As a control, we also passaged 266 13 virus in the absence of serum. After the 3 rd passage, we extracted RNA and carried out 267
RT-PCR and deep sequencing of each viral isolate. To reduce the influence of 268 sequencing error in variant calling, we produced triplicate independent library 269 preparations and averaged all replicates to determine variant frequencies. We found 270 that viruses passaged in the presence of all three narrowly focused polyclonal serum 271 samples acquired a substitution at >85% frequency at HA residues 166 or 167 (Fig. 5A) . 272
Residues 166 and 167 are likely in the same epitope based on their proximity (Fig. 5C) , 273 which is further supported by recent co-crystal structures of a monoclonal antibody with 274 similar binding patterns (18). To investigate intra-sample variability, we repeated two 275 additional viral passaging experiments with serum from donor #1. Viruses again 276 acquired substitutions at HA residue 166, but the specific amino acid change was 277 different in the different experiments (Fig. 5A) . In contrast to passaging experiments 278 involving narrowly focused sera, viruses grown in the presence of 'control sera' (i.e. 279 sera not affected in HAI assays and ELISAs by the K166Q HA mutation) did not acquire 280 substitutions in the HA epitope involving residue 166 ( Fig 5B) . Instead, viruses grown in 281 the presence of these sera acquired substitutions at residues 128, 146, 186, 189, and 282 193 of HA ( Fig. 5B-C) . Virus grown in the absence of sera did not acquire HA mutations 283 at >2.5% frequency. We detected several mutations in the other seven gene segments 284 of passaged viruses, but there were no obvious mutational pattern that distinguished 285 viruses passaged in 'narrowly focused' versus 'control' sera (Table S1) . 286 14 were present at >4.5% in our in ovo passaging experiments. We then carried out 290
ELISAs with these VLPs and found that antibodies in serum samples that were narrowly 291 focused on the HA epitope involving residue 166 had reduced binding to all of the 292 variants possessing substitutions at residues 166 and 167 ( Fig. 6A-C) . Antibodies in 293 these serum samples did not have reduced binding to VLPs possessing substitutions 294 that arose in the presence of control sera (Fig. 6A-C) , with the exception of VLPs 295 possessing a substitution at residue 128, which is near residue 166 of HA (Fig. 5C) . 296
Substitutions at residues 166 and 167 also severely reduced HAI titers of these 297 'narrowly focused' serum samples (Table 1) . In contrast, antibodies in our control 298 serum samples did not have reduced binding to VLPs possessing HAs with 299 substitutions at residues 166 and 167 ( Fig. 6D-F ) and did not have reduced HAI titers to 300 viruses with these substitutions (Table 1) . Antibodies in serum from donors #5 and #6 301 showed no reduction in binding to VLPs possessing HAs with substitutions that were 302 selected by each autologous serum sample ( Fig. 6E-F) , and no reductions in HAI titers 303 to these viruses with these mutations. Antibodies from donors #4 and #5 bound less 304 efficiently to HAs possessing substitutions that arose during passage in the presence of 305 donor #4 sera (Fig. 6D) ; however, these substitutions did not dramatically reduce HAI 306 titers (Table 1 ). These data indicate that the serum samples that were narrowly focused 307 on the HA epitope involving residue 166 efficiently selected escape mutations at 308 residues 166 and 167 that directly prevented binding of serum polyclonal antibodies, 309 similar to what has been previously reported for monoclonal antibodies. These data 310 also indicate that this experimental setup has the potential to elucidate the specificity of antigenic drift. In this study we studied individuals with antibody responses that were 318 focused on a single HA epitope that was conserved in past viral strains. We found that 319 H1N1 viruses rapidly acquired HA mutations when grown in ovo in the presence of 320 these narrowly focused serum samples, and that these substitutions directly prevented 321 the binding of serum antibodies from these individuals. Viruses grown in the presence 322 of these serum samples acquired mutations at HA residues 166 or 167. This is notable, 323 since these serum samples were collected prior to the 2013-2014 season, during which 324 a mutation at HA residue 166 of H1N1 viruses quickly rose to fixation (11). A similar 325 result using cell culture viral passaging was recently reported using convalescent sera 326 collected in 2009 from an individual in Japan (19) . We propose that influenza viruses 327 might evolve in individuals that possess narrowly focused antibody responses by 328 acquiring mutations that directly prevent antibody binding. 329
In classic studies from the 1940s and 1950s, Thomas Francis Jr. and colleagues 330 demonstrated that influenza virus exposures boost antibody responses to viral strains 331 that humans encounter early in life (5, (20) (21) (22) (23) . Some humans appear to have highly 332 focused antibody responses against influenza viruses (24), and our laboratory and 333 others have shown that H1N1 antibody responses typically recognize epitopes that are 334 conserved between contemporary viruses and viral strains that were encountered in 335 childhood (11, (25) (26) (27) . While we have previously shown that many individuals possess 336 H1N1 antibodies that target an HA epitope involving residue 166 (11), it is unknown if 337 other humans possess antibodies that narrowly target other HA antigenic sites or if the 338 majority of humans possess polyclonal responses that include many different antibody 339 specificities. One of our 'control' donors (a donor that did not have HAI antibodies 340 affected by the K166Q HA substitution) selected for viruses with substitutions at HA 341 residues 186 and 193 that directly blocked the binding of a fraction of that donor's 342 antibodies (Fig. 6 ). This suggests that the egg passaging system described in this 343 manuscript might be potentially useful for identifying previously undefined 'narrowly 344 focused' antibody specificities. 345
Our study has some limitations. We completed passaging experiments in 346 embryonated chicken eggs, but the sialic acid types that are present in eggs are much 347 different than those in the human airway. The specific amino acid changes that arose 348 experimentally (K166E, K166N, K166R, S167P) were different than those in variant 349 viruses that arose in humans (K166Q, S167T). A similar observation was made by 350
DeDiego and colleagues in H3N2 passaging experiments (28). These differences in 351 specific amino acid substitutions could be due to differences in each variant's ability to 352 bind to different sialic acid types that are in eggs versus human airways. Another 353 limitation of our study is that our mutant VLP panel was extensive but did not Despite these limitations, our study is important because it demonstrates that 358 influenza viruses can escape some types of human antibodies by simply acquiring 359 mutations that directly prevent the binding of serum antibodies. It will be important for 360 future studies to clearly define the prevalence of 'narrowly focused' serum antibody 361 responses versus more broadly reactive serum antibody responses within the human 362 population. This information will be useful to understand which antigenic escape 363 mechanisms (direct escape versus increased viral attachment) are preferentially used 364 within humans. A better understanding of influenza virus antibody specificities and anti-365 viral immune escape mechanisms will ultimately improve our ability to predict how 366 influenza viruses might change in the future. Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy AH, 
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